66 (1989) Nr. 16

TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

JAARGANG 2011 Nr. 19

A. TITEL

Overeenkomst ter bestrijding van doping;
(met Bijlage)
Straatsburg, 16 november 1989

B. TEKST

De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in *Trb.* 1991, 8.

Voor wijzigingen van de tekst van de Bijlage, zie de rubrieken J van *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44 en 244, *Trb.* 1998, 104, *Trb.* 2001, 98 en 185, *Trb.* 2003, 40, *Trb.* 2004, 194 en de rubrieken B van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24 en *Trb.* 2010, 80.

Voor enkele correcties zie *Trb.* 2008, 83 en *Trb.* 2009, 24.

De Commissie van Toezicht heeft tijdens haar 32e vergadering op 9 november 2010, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst van de wijziging luidt als volgt:

The 2011 prohibited list World Anti-Doping Code

Date of entry into force: 1 January 2011

All *Prohibited Substances* shall be considered as "Specified Substances" except Substances in classes S1, S2.1 to S2.5, S.4.4 and S6.a, and *Prohibited Methods* M1, M2 and M3.

Substances and methods prohibited at all times
(in- and out-of-competition)

S0. Non-approved substances

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (i.e. drugs under pre-clinical or clinical development or discontinued) is prohibited at all times.

Prohibited substances

S1. Anabolic agents

Anabolic agents are prohibited.

1. *Anabolic Androgenic Steroids (AAS)*

a) Exogenous[1)] AAS, including:

1-androstenediol (5α-androst-1-ene-3β,17β-diol); 1-androstenedione (5α-androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-hydroxy-5α-androstano[3,2-c] pyrazole); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone; and other substances with a similar chemical structure or similar biological effect(s).

[1)] For purposes of this section:
"Exogenous" refers to a substance which is not ordinarily capable of being produced by the body naturally.

b) Endogenous[2)] AAS when administered exogenously:

androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA); testosterone and the following metabolites and isomers:

5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; 4-androstenediol (androst-4-ene-3β,17β-diol); 5-androstenedione (androst-5-ene-3,17-dione); epidihydrotestosterone; epitestosterone; 3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-androstan-17-one; 19-norandrosterone; 19-noretiocholanolone.

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs), tibolone, zeranol, zilpaterol.

S2. Peptide hormones, growth factors and related substances

The following substances and their releasing factors are prohibited:

1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), darbepoietin (dEPO), hypoxiainducible factor (HIF) stabilizers, methoxy polyethylene glycol-epoetin beta (CERA), peginesatide (Hematide)];

2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males;

3. Insulins;

4. Corticotrophins;

5. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1), Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching;

and other substances with similar chemical structure or similar biological effect(s).

S3. Beta-2 agonists

All beta-2 agonists (including both optical isomers where relevant) are prohibited except salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regime.

The presence of salbutamol in urine in excess of 1000 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding* unless the *Athlete*

---

2) "Endogenous" refers to a substance which is capable of being produced by the body naturally.

proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of a therapeutic dose (maximum 1600 micrograms over 24 hours) of inhaled salbutamol.

S4. Hormone antagonists and modulators

The following classes are prohibited:

1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6- triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone.
2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.
4. Agents modifying myostatin function(s) including, but not limited to: myostatin inhibitors.

S5. Diuretics and other masking agents

Masking agents are prohibited. They include:

Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid and other substances with similar biological effect(s).

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide); triamterene, and other substances with a similar chemical structure or similar biological effect(s) (except drosperinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).

The use *In- and Out-of Competition*, as applicable, of any quantity of a substance subject to threshold limits (i.e. salbutamol, morphine, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjuction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

Prohibited methods

M1. Enhancement of oxygen transfer

The following are prohibited:

1. Blood doping, including the use of autologous, homologous or heterologous blood or red blood cell products of any origin.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13)

and modified haemoglobin products (e.g. haemoglobinbased blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.

M2. Chemical and physical manipulation

The following is prohibited:

1. *Tampering,* or attempting to tamper, in order to alter the integrity and validity of *Samples* collected during *Doping Control* is prohibited. These include but are not limited to catheterisation, urine substitution and/or adulteration (e.g. proteases).

2. Intravenous infusions are prohibited except for those legitimately received in the course of hospital admissions or clinical investigations.

3. Sequential withdrawal, manipulation and reinfusion of whole blood into the circulatory system is prohibited.

M3. Gene doping

The following, with the potential to enhance athletic performance, are prohibited:

1. The transfer of nucleic acids or nucleic acid sequences;

2. The use of normal or genetically modified cells;

3. The use of agents that directly or indirectly affect functions known to influence performance by altering gene expression. For exemple, Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW 1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR) are prohibited.

Substances and methods prohibited in-competition

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited *In-Competition*:

Prohibited substances

S6. Stimulants

All stimulants (including both optical isomers where relevant) are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2011 Monitoring Program[3)].

Stimulants include:

a) Non Specified Stimulants:

Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil; benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; dimethylamphetamine; etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine;

[3)] The following substances included in the 2011 Monitoring Program (bupropion, caffeine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as *Prohibited Substances*.

fenproporex; furfenorex; mefenorex; mephentermine; mesocarb; methamphetamine(*d*-); p-methylamphetamine; methylenedioxyamphetamine; methylenedioxymethamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b) Specified Stimulants (examples):

Adrenaline[4)]; cathine[5)]; ephedrine[6)]; etamivan; etilefrine; fenbutrazate; fencamfamin; heptaminol; isometheptene; levmetamphetamine; meclofenoxate; methylephedrine[7)]; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine; parahydroxyamphetamine; pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine[8)]; selegiline; sibutramine; strychnine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s).

S7. Narcotics

The following are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. Cannabinoids

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics [e.g. "Spice" (containing JWH018, JWH073), HU-210] are prohibited.

S9. Glucocorticosteroids

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

---

4) Adrenaline associated with local anaesthetic agents or by local administration (e.g. nasal, ophthalmologic) is not prohibited.

5) Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

6) Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

7) Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

8) Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

Substances prohibited in particular sports

P1. Alcohol

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold (haematological values) is 0.10 g/L.

- Aeronautic (FAI)
- Archery (FITA)
- Automobile (FIA)
- Karate (WKF)
- Motorcycling (FIM)
- Ninepin and Tenpin Bowling (FIQ)
- Powerboating (UIM)

P2. Beta-blockers

Unless otherwise specified, beta-blockers are prohibited *In-Competition* only, in the following sports.

- Aeronautic (FAI)
- Archery (FITA) (also prohibited *Out-of-Competition*)
- Automobile (FIA)
- Billiards and Snooker (WCBS)
- Bobsleigh and Skeleton (FIBT)
- Boules (CMSB)
- Bridge (FMB)
- Curling (WCF)
- Darts (WDF)
- Golf (IGF)
- Motorcycling (FIM)
- Modern Pentathlon (UIPM) for disciplines involving shooting
- Ninepin and Tenpin Bowling (FIQ)
- Powerboating (UIM)
- Sailing (ISAF) for match race helms only
- Shooting (ISSF, IPC) (also prohibited *Out-of-Competition*)
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air
- Wrestling (FILA)

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

C. VERTALING

Zie *Trb.* 1991, 8.

D. PARLEMENT

Zie *Trb.* 1995, 114.

E. PARTIJGEGEVENS

Zie *Trb.* 1991, 8 en de rubrieken F en H van *Trb.* 1995, 114.

Partij	Onder-tekening	Ratificatie	Type*	In werking	Opzeg-ging	Buiten werking
Albanië	02-02-95	15-11-04	R	01-01-05		
Andorra	29-05-02	19-09-06	R	01-11-06		
Armenië	26-05-00	23-03-04	R	01-05-04		
Australië		05-10-94	T	01-12-94		
Azerbeidzjan	28-06-02	04-11-03	R	01-01-04		
Belarus	12-09-02	15-03-06	R	01-05-06		
België	16-11-89	30-11-01	R	01-01-02		
Bosnië en Herzegovina		29-12-94	T	01-02-95		
Bulgarije	24-03-92	01-06-92	R	01-08-92		
Canada		06-03-96	O	01-05-96		
Cyprus	20-06-91	02-02-94	R	01-04-94		
Denemarken		16-11-89	O	01-03-90		
Duitsland	27-05-92	28-04-94	R	01-06-94		
Estland	14-05-93	20-11-97	R	01-01-98		
Finland	16-11-89	26-04-90	R	01-06-90		
Frankrijk	16-11-89	21-01-91	R	01-03-91		
Georgië	02-07-01	22-05-03	R	01-07-03		
Griekenland	10-10-90	06-03-96	R	01-05-96		
Hongarije		29-01-90	O	01-03-90		
Ierland	25-06-92	29-01-03	R	01-03-03		
IJsland		25-03-91	O	01-05-91		
Italië	16-11-89	12-02-96	R	01-04-96		

Partij	Onder-tekening	Ratificatie	Type*	In werking	Opzeg-ging	Buiten werking
Joegoslavië (< 25-06-1991)	10-07-91	10-07-91	R	01-09-91		
Kroatië		27-01-93	T	01-03-93		
Letland	23-01-97	23-01-97	R	01-03-97		
Liechtenstein	16-11-89	22-05-00	R	01-07-00		
Litouwen	01-04-93	17-05-96	R	01-07-96		
Luxemburg	16-11-89	21-06-96	R	01-08-96		
Macedonië, Voormalige Joegoslavische Republiek		30-03-94	T	01-05-94		
Malta	09-09-94					
Moldavië	20-02-08	27-01-09	R	01-03-09		
Monaco	09-09-03	28-11-03	R	01-01-04		
Montenegro		14-06-06	VG	06-06-06		
Nederlanden, het Koninkrijk der – Nederland: – in Europa – Bonaire – Sint Eustatius – Saba – Aruba – Curaçao – Sint Maarten	04-12-90	 11-04-95 – – – – – –	 R	 01-06-95 10-10-10 10-10-10 10-10-10 – 10-10-10 10-10-10		
Noorwegen		16-11-89	O	01-03-90		
Oekraïne	02-07-98	29-11-01	R	01-01-02		
Oostenrijk	10-05-90	10-07-91	R	01-09-91		
Polen	16-11-89	07-09-90	R	01-11-90		
Portugal	14-06-90	17-03-94	R	01-05-94		
Roemenië	16-06-94	07-12-98	R	01-02-99		
Russische Federatie		12-02-91	T	01-04-91		
San Marino	16-11-89	31-01-90	R	01-03-90		

Partij	Onder-tekening	Ratificatie	Type*	In werking	Opzeg-ging	Buiten werking
Servië		28-02-01	T	01-04-01		
Slovenië		02-07-92	T	01-09-92		
Slowakije		06-05-93	O	01-07-93		
Spanje	16-11-89	20-05-92	R	01-07-92		
Tsjechië		28-04-95	O	01-06-95		
Tunesië		26-02-04	T	01-04-04		
Turkije	16-11-89	22-11-93	R	01-01-94		
Verenigd Koninkrijk, het		16-11-89	O	01-03-90		
Zweden	16-11-89	29-06-90	R	01-08-90		
Zwitserland	16-11-89	05-11-92	R	01-01-93		

* O=Ondertekening zonder voorbehoud of vereiste van ratificatie, R= Bekrachtiging, aanvaarding, goedkeuring of kennisgeving, T=Toetreding, VG=Voortgezette gebondenheid, NB=Niet bekend

Uitbreidingen

Frankrijk

Uitgebreid tot	In werking	Buiten werking
Bassas da India	01-03-1991	
Clipperton	01-03-1991	
Europa-eiland	01-03-1991	
Frans Guyana	01-03-1991	
Frans-Polynesië	01-03-1991	
Franse Zuidelijke en Zuidpoolgebieden	01-03-1991	
Glorioso-eilanden	01-03-1991	
Guadeloupe	01-03-1991	
Juan de Nova-eiland	01-03-1991	
Martinique	01-03-1991	
Mayotte	01-03-1991	

Uitgebreid tot	In werking	Buiten werking
Nieuw Caledonië	01-03-1991	
Réunion	01-03-1991	
Sint Pierre en Miquelon	01-03-1991	
Tromelin	01-03-1991	
Wallis en Futuna	01-03-1991	

Verenigd Koninkrijk, het

Uitgebreid tot	In werking	Buiten werking
Man	01-10-1993	

Verklaringen, voorbehouden en bezwaren

Denemarken, 16 november 1989
Until further notice the signature of Denmark of this Convention does not engage Greenland and the Faroe Islands.

Griekenland, 7 juli 1994
The Government of the Hellenic Republic declares that the accession of the Former Yugoslav Republic of Macedonia to the Conventions of the Council of Europe to which the Hellenic Republic is a Contracting Party does not imply the recognition of the Former Yugoslav Republic of Macedonia by the Hellenic Republic.

Moldavië, 27 januari 2009
Until the full re-establishment of the territorial integrity of the Republic of Moldova, the provisions of the Convention will be applied only on the territory controlled effectively by the authorities of the Republic of Moldova.

G. INWERKINGTREDING

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, de rubrieken J van *Trb.* 1996, 284, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40 en *Trb.* 2004, 194, en de rubrieken G van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24 en *Trb.* 2010, 80.

De wijziging van de Bijlage van 9 november 2010 is op 1 januari 2011 in werking getreden.

Wat betreft het Koninkrijk der Nederlanden, geldt de Overeenkomst, die vanaf 1 juni 1995 voor het Europese deel van Nederland gold en vanaf 1 januari 2009 voor de Nederlandse Antillen, vanaf 10 oktober 2010 voor Nederland (het Europese en het Caribische deel), Curaçao en Sint-Maarten.

J. VERWIJZINGEN

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 2004, 194, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24 en *Trb.* 2010, 80.

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van de Bijlage van 9 november 2010 zal zijn bekendgemaakt in Nederland (het Europese en het Caribische deel), Curaçao en Sint-Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de *vierde* februari 2011.

De Minister van Buitenlandse Zaken,

U. ROSENTHAL

TRB5521
ISSN 0920 - 2218
's-Gravenhage 2011